US 11,795,167 B2
Inhibitors of (α-v)(β-6) integrin
Bryce A. Harrison, Framingham, MA (US); Matthew G. Bursavich, Needham, MA (US); Aleksey I. Gerasyuto, Flemington, NJ (US); Kristopher N. Hahn, Medford, MA (US); Kyle D. Konze, Brooklyn, NY (US); Fu-Yang Lin, Sudbury, MA (US); Blaise S. Lippa, Newton, MA (US); Alexey A. Lugovskoy, Belmont, MA (US); Bruce N. Rogers, Belmont, MA (US); Mats A. Svensson, New York, NY (US); and Dawn M. Troast, Bedford, MA (US)
Assigned to Morphic Therapeutic, Inc., Waltham, MA (US)
Filed by Morphic Therapeutic, Inc., Waltham, MA (US)
Filed on May 14, 2021, as Appl. No. 17/320,926.
Application 17/320,926 is a continuation of application No. 16/489,646, granted, now 11,046,685, previously published as PCT/US2018/019839, filed on Feb. 27, 2018.
Claims priority of provisional application 62/465,047, filed on Feb. 28, 2017.
Prior Publication US 2021/0284640 A1, Sep. 16, 2021
Int. Cl. C07D 471/04 (2006.01); A61K 45/06 (2006.01)
CPC C07D 471/04 (2013.01) [A61K 45/06 (2013.01)] 19 Claims
 
1. A compound represented by formula (I):
A-B—C  (I)
wherein:
A is

OG Complex Work Unit Chemistry
B is alkylene;
C is

OG Complex Work Unit Chemistry
R is H, alkyl, or aryl;
R1 is independently H, alkyl, halide, alkoxy, CF3, OH, NO2, —N(H)R, or NH2;
R2 is H, alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, alkoxy, —OH, N(R)C(O)R4, or —N(R)-heteroaryl;
R3 is independently alkyl, halide, alkoxy, CF3, OH, NO2, or NH2;
R4 is alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -alkylene-heterocyclyl, -alkylene-N(R)C(O)R5, or -alkylene-N(R)—SO2Me;
R5 is alkyl, or cycloalkyl;
R6 is H, or alkyl;
X is N;
Rd is H, or (C1-C6)alkyl;
a is independently 0, or 1; and
b is 0, 1, 2, 3, or 4;
or a pharmaceutically acceptable salt thereof.